Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept for Exudative Circumscribed Choroidal Haemangioma
NCT03973125Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2014
- Primary completion
- Jan 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of conbercept in choroidal hemangioma, sponsored by Sun Yat-sen University. Primary endpoint: Best-corrected visual acuity at 6 months. Status: unknown.
02
Drugs
conbercept
03
Conditions
choroidal hemangioma
Beyond the preview
Go deeper on NCT03973125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973125.